David John Adams

Title: David John Adams: Innovator in Peptide Research

Introduction

David John Adams is a notable inventor based in Kew, Australia. He has made significant contributions to the field of peptide research, particularly with his innovative work on omega conotoxin peptides. His research has implications for various medical applications, showcasing the potential of synthetic and recombinant peptides.

Latest Patents

David John Adams holds a patent for an isolated, synthetic or recombinant peptide. The patent details a specific peptide sequence: C K G K G A XaaC R XaaXaaXaaY XaaC C XaaG XaaC R XaaXaaR C SEQ ID NO: 1. In this sequence, Xaa represents various amino acids, including serine, threonine, arginine, lysine, aspartic acid, glutamic acid, glycine, alanine, valine, leucine, and isoleucine. This invention highlights the complexity and versatility of peptide design.

Career Highlights

Throughout his career, David has worked with prestigious institutions, including The University of Queensland and The University of Sydney Commercial Development & Industry Partnerships. His work in these organizations has allowed him to advance his research and collaborate with other experts in the field.

Collaborations

David has collaborated with notable colleagues such as Richard James Lewis and Geza Berecki. These partnerships have contributed to the development and refinement of his innovative peptide research.

Conclusion

David John Adams is a prominent figure in the field of peptide research, with a focus on omega conotoxin peptides. His contributions through patents and collaborations reflect his commitment to advancing scientific knowledge and innovation.